


**Publications of the Week**
**The C. elegans Embryonic Transcriptome with Tissue, Time, and Alternative Splicing Resolution**

 First Author: Adam Warner | Senior Author: Robert Waterston (pictured)  
 Genome Research | UW

 The authors used RNA-seq in *Caenorhabditis elegans* to produce transcription profiles for seven specific embryonic cell populations from gastrulation to the onset of terminal differentiation. The expression data for these seven cell populations, covering major cell lineages and tissues in the worm, revealed the complex and dynamic changes in gene expression, both spatially and temporally. [Abstract](#)
**A Coiled-Coil Masking Domain for Selective Activation of Therapeutic Antibodies**

 First Author: Vivian Trang | Senior Author: Matthew Levensgood  
 Nature Biotechnology | Seattle Genetics Inc.

 Tumor targeting has been improved by generating masked antibodies that are selectively activated in the tumor microenvironment, but each such antibody necessitates a custom design. The authors present a generalizable approach for masking the binding domains of antibodies with a heterodimeric coiled-coil domain that sterically occludes the complementarity-determining regions. [Abstract](#)
**Eleven Amino Acids of HLA-DRB1 and Fifteen Amino Acids of HLA-DRB3, 4 and 5 Include Potentially "Causal Residues" Responsible for the Risk of Childhood Type 1 Diabetes**


 First Author: Lue Ping Zhao (pictured) | Senior Author: Åke Lernmark  
 Diabetes | Fred Hutch and Benaroya Research Institute at Virginia Mason

 To overcome exceptional direct repeat (DR) sequence complexity due to high polymorphisms and extended linkage-disequilibrium among the DR loci, the authors applied a novel recursive organizer (ROR) to discover disease-associated amino acid residues. ROR distilled disease associated DR sequences down and identified eleven residues of DRB1, sequences of which retained all significant associations observed by DR genes. [Abstract](#)
[View All Publications](#)
**Awards**
**Torok-Storb Receives Minority Faculty Mentoring Award**

UW Department of Medicine


 Dr. Beverly Torok-Storb (pictured), an Affiliate Professor of Medical Oncology at UW, is this year's recipient of the 2019 Minority Faculty Mentoring Award, sponsored by the UW School of Medicine Committee on Minority Faculty Advancement and the Center for Health Equity Diversity and Inclusion. This award recognizes the achievements of senior faculty in mentoring underrepresented faculty and trainees. [Read More](#)
**Dr. John Thompson Awarded Marvin Turck Award**

UW Department of Medicine


 Dr. John Thompson (pictured, left), a Professor in the Division of Medical Oncology, is the 2019 recipient of the Marvin Turck Award, which is a career achievement award to honor individuals whose long-term contributions have defined departmental standards for patient care and teaching and made UW an outstanding educational institution. [Read More](#)
[View All Awards](#)
**Local News**
**Video Gamers Design Brand New Proteins**

UW Medicine


 A team of researchers led by Dr. David Baker (pictured) have encoded their specialized knowledge into the computer game Foldit to enable citizen scientists to successfully design synthetic proteins for the first time. Foldit was created in 2008 as a way to 'gamify' protein research. Until now, however, Foldit players could interact only with proteins that already existed. There was no way to design new ones. [Read More](#)
**Microsoft-Backed Universal Blood Test Could Start Diagnosing Disease 'within a Small Number of Years'**

GeekWire


 A groundbreaking system that would use artificial intelligence to diagnose several diseases from a single blood test may not be far off. The project, a collaboration between Microsoft and Seattle-based Adaptive Biotechnologies, could start diagnosing conditions "within a small number of years," said Peter Lee, Corporate Vice President of Microsoft Healthcare. [Read More](#)
**SORSE Technology Just Raised \$5M to Infuse Its Tech into the CBD and Cannabis Craze**

GeekWire


 SORSE Technology has been active for more than three years and has been "under the cover of darkness" for the last two, working hard on science that allows it to convert CBD and THC oils into a water-soluble product that can be infused more seamlessly into beverages, food and topicals. The company, working out of an industrial area in Seattle's Fremont neighborhood, just raised \$5 million and \$9 million to date. [Read More](#)
**Kidneys-on-a-Chip Return from Space**

UW Medicine


 Kidneys-on-a-chip that rocketed to the International Space Station in May returned via a Pacific Ocean splashdown in the same Dragon capsule. The devices, part of Tissue Chips in Space, are now back in Seattle. Researchers with the UW School of Medicine and UW School of Pharmacy undertook this project to understand the effects of microgravity on kidney function. [Read More](#)
**New Insights into Advanced Bladder Cancer**

Fred Hutch


 A first-of-its kind rapid autopsy program is helping reveal the molecular characteristics of advanced bladder cancers — and point the way toward better treatment strategies for these deadly, understudied tumors. A team of investigators including Drs. Brian Winters (pictured, right) and Navonil De Sarkar (left) examined tumors from seven patients with advanced bladder cancer who donated tissue through the rapid autopsy program. [Read More](#)
**Breaking Down HIV Exclusions in Cancer Clinical Trials**

Fred Hutch


 For reasons that date back to the earliest days of the AIDS epidemic, HIV-positive people with cancer have often been excluded from cancer clinical trials. Now, that may be changing. New research led by Dr. Tom Uldrick (pictured) at Fred Hutch has shown that patients with HIV and one of a variety of potentially deadly cancers could be safely treated with the immunotherapy drug pembrolizumab, also known by its brand name, KEYTRUDA®. [Read More](#)
**Local Drug Makers Race to Develop Non-Opioid Pain Medication**

Komo News


 Drug companies are under fire right now, accused of not doing enough to curb the opioid epidemic. Now, some drug makers hope to be part of the solution, developing pain medication that isn't addictive. A small Seattle biotech called Kineta is in the race to get a new pain relief drug on the market. Kineta's approach to pain relief originated in the depths of the sea with the cone snail, whose venom paralyzes its prey. [Read More](#)
**Struggling to Find a Fix for Type 2 Diabetes**

UW Medicine


 Intervening aggressively to roll back the onset of type 2 diabetes does work in adults, but once the medication and treatment ends, the disease always returns, according to new research from UW Medicine's Dr. Steven Kahn (pictured, left). The researchers were hoping that early, aggressive treatment of adults with prediabetes or new onset type 2 diabetes might turn back or slow the disease. But that's not what the results showed. [Read More](#)
**Immunotherapy Delays Type 1 Diabetes Diagnosis in People at High Risk**

Benaroya Research Institute at Virginia Mason


 Findings from TrialNet's Teplizumab (anti-CD3) Prevention Study has shown that a drug that targets the immune system can delay type 1 diabetes a median of two years in children and adults at high risk. Dr. Carla Greenbaum, Director of the Diabetes Research Program at Benaroya Research Institute at Virginia Mason, is the chair of TrialNet, the largest clinical trial network ever assembled to discover ways to delay and prevent type 1 diabetes. [Read More](#)
**Gene Study Suggests Drugs May Treat Some Aneurysms**

UW Medicine


 A mutation has been found in a rare form of brain aneurysm that might be treated with a drug already approved for cancer therapy. The findings from UW researchers suggest that other, more common, forms of aneurysms may be caused by yet undiscovered mutations. These might also be treated with medication instead of high-risk surgical interventions. [Read More](#)
[View All Articles](#) | [Submit an Article](#)
**Interesting Articles**
**Trump Administration Halts Fetal-Tissue Research by Government Scientists**

Nature News


 US President Donald Trump's administration is ending fetal-tissue research by government scientists and placing restrictions on academic researchers seeking grants from the National Institutes of Health (NIH) for studies involving fetal tissue. The administration said that it will set up an ethics-review board to evaluate each NIH grant application that would support research with fetal tissue, which is collected from elective abortions. [Read More](#)
[View All Interesting Articles](#) | [Submit an Article](#)
**Upcoming Events in Seattle**

June 20

5:00 PM

**Life Science Industry Networking Event**

Agora Conference Center

June 24

7:00 PM

**Science on Tap: "My Adventures Among Wild Chimpanzees: Lessons from our Closest Relatives"**

Ravenna Third Place – Cafe Arta

June 25

3:00 PM

**Life Science Xchange: Closer to Convergence**

Cambia Grove

June 26

6:00 PM

**Women in Bio: Building Strategic Partnerships**

400 Dexter Avenue, Seattle

July 18

11:30 AM

**2019 Hutch Award Luncheon**

T-Mobile Park

[View All Events](#) | [Submit an Event](#)
**Science Jobs in Seattle**
**Senior/Principal Scientist, Pharmacology**

Zymeworks

**Senior Scientist, AAV Development, Allogeneic Cell Therapy**

Celgene

**Senior Scientist, Oncology & Discovery**

Bluebird Bio

**Postdoctoral Research Fellow, Translational Gene Therapy**

Fred Hutch

**Scientific Technical Writer**

Adaptive Biotechnologies

[View 34 Other Science Jobs](#) | [Submit a Job](#)
**STEMCELL Jobs**
**Process Development Scientist, Protein Production, Vancouver**

STEMCELL Technologies

**Scientist, Contract Assay Services, Vancouver**

STEMCELL Technologies

**Program Manager, Primary Cells, Vancouver**

STEMCELL Technologies

**Process Development Scientist, Biologics, Vancouver**

STEMCELL Technologies

**Research Associate, Immune Cell Culture, Vancouver**

STEMCELL Technologies

[View 86 Other STEMCELL Jobs](#) | [Submit a Job](#)

 Please inform us of any important Seattle news that we may have missed by e-mailing us at [info@scienceinseattle.com](mailto:info@scienceinseattle.com).

BROUGHT TO YOU BY


[STEMCELL Technologies](#)  
 Products | Services

[STEMCELL's Science Newsletters](#)  
 Free Weekly Updates on Your Field

[The Stem Cell Podcast](#)  
 Interviews and Updates on Stem Cell Science